Novel Target for Triple Negative Breast Cancer Immunotherapy
Targeting Eya3 protein (belonging to the Eya family of proteins) shown to make check-point inhibitors more effective in triple negative breast cancer. This finding is the result of a University of Colorado Cancer Center study that hoped to determine what drove the breast cancer cells to produce PD-L1 protein in the first place in order to try and make immunotherapy even more effective in combating cancer.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer